LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced that the Marketing Authorization Application (MAA) for
neratinib has been validated by the European Medicines Agency (EMA).
Validation of the MAA confirms that the submission is complete and
starts the EMA's formal review process. The potential indication for
neratinib is for the extended adjuvant treatment of HER2-positive early
stage breast cancer that has previouslymore...